In case of the woman, the transplantation process was uncomplicated. The man lost the CCR5Δ32/Δ32 graft and died of recurrent Hodgkin’s lymphoma within a year. Both patients underwent a haplo-cord transplant with CCR5Δ32/Δ32 cord blood units. Two HIV-1 positive middle-aged patients were treated: a man who developed Hodgkin’s lymphoma and a woman who developed AML. 10.1126/science. test the potential of haplo-cord stem cell transplantation for HIV cure, the present observational study enrolled HIV-1-infected individuals who required allogeneic stem cell transplantation due to an underlying malignant disease. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, and Richman DD (1997). Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, and Siliciano RF (2003). Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. HIV Surveillance Report 33.Ĭhun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, et al. Diagnoses of HIV infection in the United States and dependent areas. Global HIV & AIDS statistics - Fact sheet. ![]() HIV CCR5 dela 32 transplant HIV cure HIV remission.Ĭopyright © 2023 The Authors. ![]() ![]() CCR5Δ32/Δ32 haplo-cord transplant achieved remission and a possible HIV-1 cure for a person of diverse ancestry, living with HIV-1, who required a stem cell transplant for acute leukemia. Immune reconstitution was associated with (1) loss of detectable replication-competent HIV-1 reservoirs, (2) loss of HIV-1-specific immune responses, (3) in vitro resistance to X4 and R5 laboratory variants, including pre-transplant autologous latent reservoir isolates, and (4) 18 months of HIV-1 control with aviremia, off antiretroviral therapy, starting at 37 months post-transplant. Peripheral blood chimerism was 100% CCR5Δ32/Δ32 cord blood by week 14 post-transplant and persisted through 4.8 years of follow-up. We report the first remission and possible HIV-1 cure in a mixed-race woman who received a CCR5Δ32/Δ32 haplo-cord transplant (cord blood cells combined with haploidentical stem cells from an adult) to treat acute myeloid leukemia (AML). Previously, two men were cured of HIV-1 through CCR5Δ32 homozygous (CCR5Δ32/Δ32) allogeneic adult stem cell transplant.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |